Clinical Trial Update
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Additionally, topline data from the Travelan® study has been delayed due to a government shutdown, now expected at the end of November. The results from this study will influence Immuron's dosing strategy for an upcoming meeting with the FDA regarding Travelan®.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immuron
- Immuron launch PROIBS for IBS
- Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.
- Immuron Q1 FY26 YoY growth
- Immuron Submits IMM-529 IND to FDA
- Immuron Letter to Shareholders – Projects Update
Later from Immuron
- Immuron Announces Clinical Trial Update
- IMM-529 IND approved by FDA
- Immuron New U.S. Department of Defense Award & Clinical Trial Update
- Uniformed Services University to Release Topline Data
- Immuron Reports Continued Sales Growth
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron